DGEN Stock Overview
Deltagen Inc. provides drug discovery tools and services to the biopharmaceutical industry.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Deltagen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.000001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -99.99% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| DGEN | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | -6.3% | -3.5% |
| 1Y | n/a | -6.3% | 20.2% |
Return vs Industry: Insufficient data to determine how DGEN performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how DGEN performed against the US Market.
Price Volatility
| DGEN volatility | |
|---|---|
| DGEN Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DGEN has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DGEN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Robert Driscoll | www.deltagen.com |
Deltagen Inc. provides drug discovery tools and services to the biopharmaceutical industry. The company offers a suite of programs designed to enhance the efficiency of drug discovery, including access to biological models, as well as small-molecule and secreted protein drug targets. It also provides target validation data in the areas of immunology and metabolic diseases.
Deltagen Inc. Fundamentals Summary
| DGEN fundamental statistics | |
|---|---|
| Market cap | US$32.00 |
| Earnings (TTM) | -US$46.00k |
| Revenue (TTM) | US$770.00k |
0.0x
P/S Ratio0.0x
P/E RatioIs DGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DGEN income statement (TTM) | |
|---|---|
| Revenue | US$770.00k |
| Cost of Revenue | US$4.00k |
| Gross Profit | US$766.00k |
| Other Expenses | US$812.00k |
| Earnings | -US$46.00k |
Last Reported Earnings
Dec 31, 2015
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did DGEN perform over the long term?
See historical performance and comparison